CNSP News and Press, CNS Pharmaceuticals Inc. From 10/13/22

A new study has discovered a crucial new piece of information for the treatment and prevention of brain tumors. The study was led by Mount Sinai Hospital’s Lunenfeld-Tannenbaum Research Institute, in collaboration with the Mayo Clinic Center for Individualized Medicine and the May...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in The American Bra...

CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run PR Newswire HOUSTON , Oct. 10, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Compa...

CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA...

LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) , a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today annou...

With abortion bans going into effect in different regions in the country, oncologists are trying to gauge how these new laws will impact treatment options for cancer patients who are pregnant. Cancer coincides with about one in every thousand pregnancies, with cancers such as leukemias, ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant hea...

University of California San Diego recently began to administer a new radiation therapy for brain cancer treatment that slows down tumor regrowth and protects healthy tissue in the brain. UC San Diego neurosurgeon Marc Schwartz stated that this new therapy could help improve the qualit...

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the o...

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM PR Newswire Sites in France and Spain now open and actively enrolling Enrollment ...